Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Planet MicroCap Showcase (May 2024)
25 slides from Shuttle Pharmaceuticals's conference presentation, May 2024
Slide 1: Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation Planet MicroCap Showcase May 2024
Slide 2: Forward Looking Statements
Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com
Slide 3: Company Overview
Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics Ropidoxuridine is a clinical stage, orally-administered cancer radia
Slide 4: The Fundamental Problem of Radiation Therapy
The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy The radiation dose determines cancer curability Adjacent normal tissues are dose-limiting Sensitizer Radiation sensitizer
Slide 5: Radiation Sensitizers
Radiation Sensitizers Cancers are resistant to cure by radiation therapy because tumors are surrounded by radiation sensitive normal tissues that limit the maximum treatment dose. 5 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Slide 6: Market Opportunity – Cancer is the #2 cause of death in the U.S.
Market Opportunity – Cancer is the #2 cause of death in the U.S. Radiation sensitizers can improve outcomes in many cancer ~ 1.7 M new cases annually in the U.S. ~ 400,000#2 patients with local/regional cancers are candidates for sensitizers #5 ~ “Off-label” use of radiation sensitizing drugs predom
Slide 7: Pipeline of Radiation Sensitizers and HDAC Inhibitors
Pipeline of Radiation Sensitizers and HDAC Inhibitors The pipeline is composed of the clinical lead radiation sensitizer Ropidoxuridine and selective HDAC (histone deacetylase) inhibitors that sensitize cancers by inhibiting epigenetic functions to stimulate the immune system targeting irradiated ca
Slide 8: Ropidoxuridine (IPdR) – How does it work?
Ropidoxuridine (IPdR) – How does it work? Ropidoxuridine (IPdR) is the prodrug of IUdR Ropidoxuridine (IPdR) is metabolized to IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical IUdR, incorporates into DNA, and trials in glioblastoma, anaplastic astrocytoma
Slide 9: Ropidoxuridine (IPdR) – Clinical Development
Ropidoxuridine (IPdR) – Clinical Development Phase I and pharmacology study of Ropidoxuridine (IPdR) as prodrug for iododeoxyuridine-mediated tumor radiosensitization in advanced GI cancers undergoing radiation (Study funded by NIH SBIR contract awarded to Shuttle Pharma with Brown University RIH
Slide 10: Summary of Recent Activities
Summary of Recent Activities The campaigns to manufacture and formulate the drug product have been completed. The Phase II clinical trial was designed incorporating FDA guidance. The IND was approved by the FDA and a safe to proceed letter was received on January 5, 2024. Five academic clini
Slide 11: Selective HDAC inhibitors
Selective HDAC inhibitors Radiation sensitization and immune modulation. 11 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Slide 12: HDAC Inhibitor Platform: Overview
HDAC Inhibitor Platform: Overview Shuttle Pharma has discovered novel HDAC inhibitors using proprietary technology. SP-2-225 is our candidate lead HDAC6 inhibitor for RT and immunotherapy treatment. SP-225 testing will define post-RT immune response Acetylated histones enhancement for a role i
Slide 13: SP-2-225: Selective HDAC6 Inhibitor
SP-2-225: Selective HDAC6 Inhibitor SP-2-225 inhibits HDAC6, prolongs macrophage polarization in M-1 state, resulting in an enhanced inflammatory Acetylated histones Active transcription response to immunogenic cancers and Irradiated tumors. De-acetylated histones Inactive transcription Noonepalle S
Slide 14: Therapeutics: Clinical Development Strategy
Therapeutics: Clinical Development Strategy Shuttle Pharma has a broad pipeline to improve clinical outcomes of patients treated with radiation therapy for cancer Therapy Priority #1: Clinical development of Ropidoxuridine & RT Perform the Phase II clinical trial of Ropidoxuridine & RT in brain
Slide 15: Diagnostics
Diagnostics PC-RAD Test PSMA-B ligand 15 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Slide 16: Diagnostics: Market Opportunity
Diagnostics: Market Opportunity Predictive biomarkers for prostate cancers ~ 268,000 new prostate cancer cases annually in the U.S. (incidence) #2 ~ 3,100,000 patients currently live with prostate cancer in the U.S. (prevalence) ~ 66,000 patients with localized radiation (30%) receive primary RT for
Slide 17: Diagnostics: Competitive Landscape
Diagnostics: Competitive Landscape #2 ~1.8M ~900,000 ~50,000 17 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Slide 18: Intellectual Property Portfolio for Diagnostics
Intellectual Property Portfolio for Diagnostics PC-RAD Test (predictive biomarker) Intellectual property for the diagnostic predictive biomarker exclusive license (Georgetown University): Title: “Predictive Biomarkers for Adverse Effects of Radiation Therapy” U.S. Application No. 17/476,148 file
Slide 19: Diagnostics: PC-RAD-Test Kit
Diagnostics: PC-RAD-Test “Kit” Calibrants for standard vials QC and internal standards NIST Plasma reference standard User Manual Guide USB Stick with proprietary software 2 x 96 well plate for sample preparation Pre-formatted mat/plate cover Metabolite panels discovered to define pr
Slide 20: Diagnostics: Product Development – PSMA-B
Diagnostics: Product Development – PSMA-B The prostate-specific membrane antigen (PSMA) is an enzyme located on the outside of prostate cancer cells. The PSMA ligand binds to the enzyme, PSMA dimerizes and is internalized into the cell. Diagnostic molecules for PET scanning are created by attaching
Slide 21: Clinical Development Strategy for Diagnostics
Clinical Development Strategy for Diagnostics Develop the PC-Rad Test intellectual property as a predictive diagnostics test Diagnostic Priority #1: Predictive Biomarker for Prostate Cancer Establish and validate the predictive assay in the context of use (COU) for FDA approval. Perform a muti-i
Slide 22: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of December 31, 2023 Common Stock 16,609,320 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 160,744 Closing Stock Price* $0.41 RSUs Outstanding 197,855 52 Wk High/Low* $0.35 - $2.75 Warrants Outst
Slide 23: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Founder & CEO of Shuttle Served as President Served as CFO of Pharma since 2012; Chairman, & COO of Shuttle Shuttle Pharma since Board of Directors 2017 Pharma since 2012 2019 Member, Board of Directors, MBA George MHSA George Neopharm Inc. 1990 Wash
Slide 24: Board of Directors
Board of Directors Steve Richards, MBA, CPA Milton Brown, MD, PhD Bette Jacobs, PhD Chris Senanayake, PhD Joshua Schafer, MBA Businessman Vice Dean for Research Professor/Distinguished Scholar Chief Commercial Officer CEO, TCG GreenChem CEO, Endurance Media East Virginia Medical School Georgetown Un
Slide 25: Thank You
THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com
Shuttle Pharmaceuticals Holdings — Planet MicroCap Showcase (May 2024) on 6ix